We explore the role of the mitochondrial genome in idiopathic Parkinson’s disease. Our aim is to identify cellular pathways, which may be targeted for therapeutic intervention. For monogenic Parkinsonism, we aim to understand why some individuals do not manifest any signs of the disease despite the presence of a mutation. We want to uncover mechanisms that could be modulated to delay the onset.